Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate ...

E1s and E2s first work generically across the cell to activate and prepare ubiquitin for attachment. E3 ligases then ensure that the tag is added to the right protein; as such, hundreds of specific ...

Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate ...

MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

This study presents an important discovery regarding the diversity and evolution of gall-forming microbial effectors. Supported by convincing computational structural predictions and analyses, the ...

All biological function is dependent on how different proteins interact with each other. Protein-protein interactions ...

DeepMind's AlphaFold, a generative AI tool, has achieved a milestone in biology by accurately predicting protein structures, ...

A new study shows that enhancing activity of a specific component of 'NMDA' receptors normalizes protein synthesis, neural activity and seizure susceptibility in the hippocampus of fragile X lab mice.

Northwestern University researchers have identified structural features in engineered cell receptors that correlate with ...

Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems. PPIs are activated in the acid-producing cells of the ...

A team from the University of Washington led by Nobel laureate David Baker is using artificial intelligence to design ...

Evo 2 now includes information from humans, plants, and other eukaryotic species to expand its capabilities in generative functional genomics.